Come and find out! Has giritinib been included in the medical insurance catalog in China?

The U.S. Food and Drug Administration (FDA)approved theFLT3 inhibitor Gilitinib (Gilteritinib) is the first second-generationFLT3 inhibitor compound on the market. Giritinib is indicated for adult patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3 mutations identified by an FDA-approved test. The starting dose is 120 mg (three 40 mg tablets) orally, with or without food, administered at the same time once daily until disease progression or unacceptable toxicity. Treatment for at least 6 months is recommended to allow time for clinical response. Before initiating treatment, blood counts, serum chemistries, and creatine phosphokinase should be monitored. Follow up at least weekly for the first month, every other week for the second month, and monthly thereafter. ECGs should be obtained before starting treatment, on days 8 and 15 of the first cycle, and before the start of the second and third cycles.

The original drug of giritinib has been launched in China. Since it has only been on the domestic market for a short period of time, the relevant policies of medical insurance have not yet been adopted, so it has not been included in the scope of medical insurance. The specific time is not yet clear. The price of the common specification of 40mg*42 tablets per box may be more than 20,000 yuan, and the price of the Hong Kong version of the original drug is about 90,000 yuan per box. The price of the European version of the original drug, 40mg*84 tablets, per box listed overseas is around RMB 210,000 (the price may fluctuate due to exchange rates), which is very expensive. Generic drugs of giritinib are currently produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*84 tablets per box produced by a Laos pharmaceutical factory is more than 4,000 yuan (the price may fluctuate due to the exchange rate).